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Abstract: An 84-year-old lady with slowly progressive limb and axial muscle weakness with 
onset in her teens was referred for genetic investigations. Targeted next generation 
sequencing (NGS) revealed a homozygous mutation GYG1 in exon5:c.487delG:p.D163fs, 
confirming the diagnosis of Polyglucosan Body Myopathy 2 (PGBM2). Retrospective review 
of muscle pathology revealed a florid vacuolar myopathy with histochemical and 
ultrastructural features consistent with a polyglucosan storage myopathy. No cardiac 
symptoms were reported. Our case is consistent with the core phenotype of GYG1-related 
PGBM2 apart from an early onset of weakness without cardiac symptoms. The presence of α-
amylase resistant PAS-positive material in skeletal muscle biopsy of patients with slowly 
progressive limb girdle muscle weakness should prompt the search for GYG1 mutations. This 
case highlights the combined role of muscle pathology and NGS in the molecular resolution 
of undiagnosed patients with undiagnosed neuromuscular conditions. 
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Limb Girdle Muscular Dystrophy (LGMD)  
Introduction: 
 
Glycogen is a highly branched polymer of glucose residues, linked by α-(1,4)- and α-
(1,6)-glycosidic bonds and its synthesis involves a series of co-ordinated reactions catalysed 
3 
 
by various enzymes. Pathogenic mutations in genes that encode enzymes involved in 
glycogen synthesis and degradation cause abnormal glycogen accumulation within a variety 
of cells to include skeletal and cardiac muscle, liver, and others (Glycogen Storage Disorders 
- GSDs). Related symptoms may include muscle weakness, hepatic dysfunction and 
cardiomyopathy.  
The GYG1 gene encodes the skeletal muscle isoform of glycogenin (glycogenin-1), a 
protein which plays an important role in the biosynthesis of glycogen. Glycogenin-1 acts as a 
glycosyl transferase to catalyse synthesis of short, 7-13 residue glucose polymers from UDP-
glucose by a process of auto-glycosylation of a tyrosine residue. This is followed by 
elongation and branching of the glucose primer chains by glycogen synthase and branching 
enzymes, encoded by GYS1 gene in muscle and GBE1 genes respectively, to produce 
glycogen. Mutations in GYG1 have been shown to result in reduced, absent or functionally 
abnormal glycogenin-1, leading to defective priming of glycogen synthesis, glycogen 
depletion in skeletal muscle and abnormal glycogen accumulation in cardiac muscle 
(Glycogen Storage Disease type XV - GSDXV).(1, 2) 
Polyglucosan bodies consist of aggregates of abnormal amylopectin like 
polysaccharides with less branching than normal glycogen and variable degree of resistance 
to α-amylase digestion. Seen as fibrillar structures on electron microscopy, their 
accumulation in muscle has been described in disorders of glycogen metabolism (GSDIV, 
VII and XV), AMP- activated protein kinase deficiency, RBCK1 –related disease and Lafora 
body disease.(2) Polyglucosan body accumulation with associated slowly progressive 
proximal myopathy has been recently reported with a recurring intronic GYG1 homozygous 
mutation (c,143 + 3G > C).(3, 4) Homozygous or compound heterozygous mutations in GYG1 
may cause Polyglucosan Body Myopathy 2 (PGBM2) (OMIM #616199). The clinico-
pathological spectrum of GYG1-disease is expanding, to include distal myopathy. We report a 
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patient with progressive muscle weakness and a late diagnosis of GYG1-associated PGBM2 
established by Next Generation Sequencing (NGS). 
 
Case Report 
An 84-year-old lady with a history of chronic and slowly progressive muscle weakness with 
onset in her teens, affecting axial, proximal and distal limb muscles in an asymmetrical 
distribution, was referred for diagnostic investigations. She had a normal childhood and was 
good at sport. She used to do ballet and tap dance until the age of 15 years when she began to 
notice that she could not “hurry” anymore as her agility was reduced. She reported proximal 
muscle weakness from 15 years of age, initially more evident in her lower limbs. Symptoms 
gradually progressed and by 40 years of age she had difficulty climbing stairs and in her 50s 
she had to move to a ground floor flat. She was unable to mobilise without a rollator at the 
age of 70 years, which she used for the last 15 years. The last two years were particularly 
more difficult as weakness limited her daily activities including showering and cooking. She 
gradually noticed difficulties opening cans and bottles due to distal hand weakness which 
developed over many years, but she could not recall the exact age of onset.  In the 1950s, 
when she was in her 20s she was given a clinical diagnosis of limb girdle muscular 
dystrophy.. Throughout her life, she had no symptoms of myoglobinuria, cardiac, respiratory 
or gastrointestinal involvement. Her family history was unremarkable for neuromuscular 
diseases and she had no offspring.  
A quadriceps muscle biopsy was performed 30 years ago, when she was 58 years old 
to exclude polymyositis because she developed transient myalgia and tenderness around the 
shoulder girdle muscles. According to the clinical synopsis in the biopsy report: CK was 122 
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IU/L. The biopsy showed a vacuolar myopathy with accumulation of PAS-positive material 
leading to a diagnosis of an uncertain form of GSD.  
The patient requested a referral to our tertiary centre in her 80s for a comprehensive 
review and further investigation, given the rapid developments in the field of neuromuscular 
disease since the 1990s. On physical examination at the age of 84, there was evidence of 
global muscle atrophy, moderate bilateral scapular winging and asymmetrical weakness in 
the axial and limb muscles (Table 1). Cranial musculature was spared. There were no cardiac 
symptoms or abnormal clinical signs on examination. 
 Left Right 
Neck muscles 
(Flexion, Extension, Rotation) 
4 4 
Trapezius 4 4 
Deltoid 2 2 
Biceps  3 2 
Triceps 4 3 
Pronation / Supination 3 / 3 4 / 4 
Flexion / Extension at Wrist 3 / 2 4 / 3 
Finger Flexion / Extension 4 / 3 5 / 3 
Abduction of the Fingers 3 3 
Hip Flexion / Extension 3 / 4 3 / 4 
Leg Flexion / Extension 3 / 3 3 / 4 
Dorsiflexion of the Feet 3 3 
Plantar Flexion 4 4 
Table 1: MRC Score. Physical exam performed at the age of 84. 
 
Serum creatine kinase (CK) was essentially normal (CK: 147 IU/L, normal range 26-
140). Random blood glucose and serum lactate were normal. Erythrocyte glycogen content 
was reported to be low at 4.9 μg/g of haemoglobin (10-120) on an initial sample, but was low 
normal on subsequent testing (10 μg/g). Enzyme analysis (blood sample) for acid alpha 
glucosidase, phosphorylase b kinase and beta galactosidase was normal. Neurophysiology 
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studies showed myopathic features. ECG was within normal limits. The patient declined to 
have a cardiac echo. 
Genetic investigation by NGS Illumina “TruSight One” enrichment panel designed to 
screen for 60 relevant genes associated with rhabdomyolysis (mostly reviewed on (5)) was 
performed as it covered all GSD related genes. The rhabdomyolysis panel confirmed GYG1 
homozygous mutation in exon 5 (c.487delG:p.D163fs). The change was an aspartic acid to a 
threonine at amino acid position 163 and a shift in the reading frame, resulting in a premature 
stop codon at position 167 (D163Tfs*5). This mutation was present in the control population 
but only in the heterozygous state (57 out of 120,474) and not as a homozygote and, 
predominantly in North European individuals (52/66,388). This concurs with the lack of 
family history and the presence of this change in a non-consanguineous pedigree. The 
frequency of heterozygotes suggests that LGMD-like phenotype due to this mutation may not 
be that rare in the European population.  
Following the genetic diagnosis, we tried to retrieve the historical biopsy performed 
many decades ago in a different hospital in order to review the muscle pathology. 
Unfortunately, the original stained slides could not be traced. A single formalin-fixed and 
paraffin-embedded (FFPE) block was identified and retrieved for work-up (Figure 1). 
Sections were cut and stained from the archival paraffin block. Staining for PAS and PAS 
with diastase digestion was performed as per previously described protocols.(6) 
Immunostaining was performed using antibodies against fast myosin (Leica Microsystems 
(Novocastra), WB-MHCf), slow myosin (Leica Microsystems (Novocastra), WB-MHCs), 
ubiquitin (Santa-Cruz, SC-8017) and p62 (Abcam  ab56416). 
The biopsy showed marked myopathic changes including patchy, asymmetric fatty 
infiltration within fascicles and increased fibre size variation. There was overall slow fibre 
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predominance with preferential fast fibre atrophy. Over 80% of fibres appeared vacuolated, 
containing polymorphic subsarcolemmal and internal basophilic inclusions that were 
intensely PAS-positive. The inclusions ranged from discrete large ‘lakes’ to myriad smaller 
deposits to fine ‘dust-like’ material. Fibres cut longitudinally revealed skip lesions. Virtually 
all of this material was resistant to α-amylase digestion in keeping with polyglucosan 
accumulation, and many such fibres appeared depleted of glycogen.  The storage material 
was also immunoreactive for desmin and ubiquitin. CD68 labeling was very sparse and 
unrelated to the vacuolar storage. A region of interest marked on the Haematoxylin and Eosin 
stained section was mapped to and cut out from the paraffin block, and re-processed for 
electron microscopy. Although preservation was sub-optimal, presence of fibrillar 
polyglucosan storage material was confirmed. 
   
Discussion 
To date, only a few patients with GYG1 mutations and a neuromuscular phenotype are 
reported. In 2010, Moslemi et al (7) first described a young male with muscle weakness, 
cardiomyopathy and cardiac arrhythmia caused by bi-allelic mutations in GYG1. Deltoid 
muscle biopsy of this patient showed glycogen depletion in skeletal muscle, but accumulation 
of PAS-positive material in cardiac myocytes. The exact nature of the PAS-positive material 
in the reported patient could not be established. Subsequently, Malfatti et al (4) presented 7 
patients with a slowly progressive skeletal myopathy of juvenile or adult onset with 
polyglucosan bodies on muscle biopsy, but no cardiac involvement. DNA analysis revealed 
homozygous or compound heterozygous mutations in GYG1 gene and the authors suggested 
that the varying phenotypes are probably related to the type of GYG1 pathogenic variant. In 
our case, the only material available for pathological reassessment was a FFPE block. In 
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contrast to the pathology of cases described by Malfatti et al, the PAS+ inclusions in our 
patient’s biopsy were strongly α-amylase resistant, and there was variable glycogen depletion 
in fibres containing polyglucosan. The true extent of glycogen depletion in our case is 
difficult to ascertain due to the nature of the biopsy material being formalin fixed and paraffin 
processed, and at least part of the glycogen depletion may relate to the processing effect. As 
there was no record of previous electron microscopic examination, we re-processed a region 
of interest from the paraffin embedded tissue for electron microscopy, and successfully 
demonstrated fibrillar storage material in keeping with polyglucosan, albeit of an inferior 
quality to freshly processed tissue for electron microscopy. Our case demonstrates the utility 
of this technique for ultrastructural assessment of structural abnormalities or storage material 
from cases where no other tissue except FFPE may be available. The slow fibre 
predominance and fast fibre atrophy may suggest a metabolic adaptation to the defective 
glycogen metabolism.  
Muscle MRI in individual cases has shown preferential involvement of deltoids and 
the gluteal muscles and could be used as a non-invasive tool to characterise the pattern of 
muscle involvement and monitor progression. (8, 9) Akman et al. reported five adult patients 
with polyglucosan myopathy from four unrelated Sardinian families, all with the same 
autosomal recessive GYG1 mutation. Taking into consideration all published case reports, the 
most common mutation described to date is a single nucleotide substitution at donor splice 
site in intron 2 c.143+3G>C.(2, 4, 7, 10) Majority of PGBM2 patients described to date 
developed muscle weakness in adulthood, as opposed to our patient who presented symptoms 
since her teens.(11) Even though late onset myopathy with progressive symmetrical limb 
girdle weakness is the most common muscle phenotype; early onset, facial muscle weakness, 
asymmetry of limb muscle weakness and distal limb weakness (as described in our case), 
myalgia, exercise intolerance and fluctuation in symptoms have all been reported.(3, 4, 8, 9) 
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A purely cardiac phenotype in 3 patients has been published by Oldfors et al in 2017 (12), 
with the genetic defect being c.304G > C, p.Asp102His mutation in exon 3 of the GYG1 
gene. The authors think that cardiomyopathy and cardiac failure relate to cellular overload of 
polyglucosan material, leading to cell death and secondary fibrosis.  
The pathogenesis of polyglucosan body accumulation in GYG1 myopathy is not fully 
understood, but is thought to be related to ubiquitin-proteasomal and autophagic degradation 
pathways.(10) Many of the polyglucosan inclusions in the reported case labeled with 
ubiquitin, suggesting protein accumulation and activation and/or overloading of the ubiquitin-
proteosomal pathway. 
Our case describes a patient with progressive muscle weakness who was originally 
diagnosed with LGMD and subsequently polymyositis based on her initial clinical 
presentation. Later on, following muscle biopsy, her diagnosis was modified to ‘an uncertain 
form of GSD'. The genetic diagnosis of GYG1-related PGBM2 was established by targeted 
NGS, almost 70 years after disease presentation, highlighting the importance of NGS as a 
diagnostic tool when assessing undiagnosed patients presenting with muscle weakness. Our 
case extends the clinical phenotype of this disease to presentation in teens with slow 
progression over many years. A comprehensive muscle biopsy review was undertaken from a 
block of paraffin embedded tissue including D-PAS and p62 staining following the genetic 
diagnosis. The findings were consistent with a polyglucosan storage myopathy, reaffirming 
the genetic diagnosis. The original tissue diagnosis of an ‘uncertain form of GSD’ may reflect 
the fact that PAS staining with diastase digestion was not performed, and there was no 
ultrastructural assessment of the substantial storage material evident on light microscopy. Our 
case highlights the need for routine inclusion for diastase-PAS in the histochemical panel for 
diagnostic muscle biopsies. In the context of NGS-based approach becoming increasingly 
established for resolving molecularly unconfirmed cases, our case represents a good example 
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of ‘reverse pathology’ where any type of archival material when available should be 
reviewed to ascertain compatibility with the genetic diagnosis, and/or extension of known 
pathological phenotypes associated with a particular known disease causing gene.   
Unfortunately we were unable to perform a detailed cardiac investigation with 
echocardiography or cardiac MRI on our patient as she declined the investigations due to 
travelling difficulties as a consequence of her muscle impairment. In the absence of cardiac 
symptoms, normal cardiovascular system on bedside examination, normal ECG and longevity 
we presume that she had a pure skeletal muscle phenotype, with no significant cardiac 
involvement. Further studies should be performed to understand the use of erythrocyte 
glycogen content as a potential screening test in this group of patients. 
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Figure 1. Quadriceps muscle biopsy performed at 58 years of age; only paraffin-embedded 
tissue was available for re-analysis. There is marked myopathic variation in fibre size (A, 
haematoxylin & eosin). Several fibres appear vacuolated, containing subsarcolemmal and 
internal basophilic inclusions that are intensely PAS-positive (B) and a majority are strongly 
α-amylase resistant consistent with polyglucosan storage (C). Many fibres containing 
polyglucosan material show partial glycogen depletion. Ultrastructural examination of the re-
processed paraffin-embedded material confirms electron-dense fibrillary polyglucosan 
storage (D, higher magnification inset). Scale bar in A-C = 100 microns. 
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